MindRank AI (德睿智药) focuses on the research and development of new AI drugs, and has a one-stop AI-driven drug discovery platform-the medical knowledge graph PharmKG™️ and the drug design platform Molecule Pro™️. In 2018, the De Rui Zhi Pharmaceutical team has begun technical research and development, perfecting and verifying the capabilities of the self-developed artificial intelligence pharmaceutical platform. The team returned to China in November 2020 and established De Rui Zhiyao in Hangzhou, hoping to bring the mature one-stop AI drug research and development technology and development model back to China, and quickly start the commercialization cooperation and pipeline development of the platform.